Parks NE[au] - Search Results

Year	Number of Results
2010	1
2012	3
2013	1
2014	2
2015	1
2016	1
2017	3
2018	3
2019	2
2020	2
2021	2
2022	1

1

Dietary interventions for multiple sclerosis-related outcomes.

Parks NE, Jackson-Tarlton CS, Vacchi L, Merdad R, Johnston BC. Parks NE, et al. Cochrane Database Syst Rev. 2020 May 19;5(5):CD004192. doi: 10.1002/14651858.CD004192.pub4. Cochrane Database Syst Rev. 2020. PMID: 32428983 Free PMC article.

2

Metabolic and Toxic Myelopathies.

Parks NE. Parks NE. Continuum (Minneap Minn). 2021 Feb 1;27(1):143-162. doi: 10.1212/CON.0000000000000963. Continuum (Minneap Minn). 2021. PMID: 33522740 Review.

3

Navigating the TOR of Multiple Sclerosis.

Parks NE. Parks NE. Can J Neurol Sci. 2020 Jul;47(4):435-436. doi: 10.1017/cjn.2020.76. Epub 2020 Apr 24. Can J Neurol Sci. 2020. PMID: 32326985 No abstract available.

4

Neuroradiologic manifestations of Erdheim-Chester disease.

Parks NE, Goyal G, Go RS, Mandrekar J, Tobin WO. Parks NE, et al. Neurol Clin Pract. 2018 Feb;8(1):15-20. doi: 10.1212/CPJ.0000000000000422. Neurol Clin Pract. 2018. PMID: 29517068 Free PMC article.

5

Erdheim-Chester Disease and Palatal Tremor.

Parks NE, Purdy RA. Parks NE, et al. Can J Neurol Sci. 2018 Jan;45(1):90-91. doi: 10.1017/cjn.2017.259. Epub 2017 Nov 17. Can J Neurol Sci. 2018. PMID: 29145922 No abstract available.

6

NEDA treatment target? No evident disease activity as an actionable outcome in practice.

Parks NE, Flanagan EP, Lucchinetti CF, Wingerchuk DM. Parks NE, et al. J Neurol Sci. 2017 Dec 15;383:31-34. doi: 10.1016/j.jns.2017.10.015. Epub 2017 Oct 13. J Neurol Sci. 2017. PMID: 29246616 Review.

7

Dietary interventions for multiple sclerosis-related outcomes: Summary of a cochrane review.

Hartman LJ, Ne P, Cs JT, Vacchi L, Merdad R, Bc J. Hartman LJ, et al. Among authors: ne p. Explore (NY). 2022 Jan 2:S1550-8307(21)00274-3. doi: 10.1016/j.explore.2021.12.007. Online ahead of print. Explore (NY). 2022. PMID: 35031230 No abstract available.

8

Clinical Course of Relapsing Remitting Multiple Sclerosis Post-Natalizumab.

Fiander MDJ, Bhan V, Stewart SA, Parks NE. Fiander MDJ, et al. Among authors: parks ne. Can J Neurol Sci. 2019 Jul;46(4):455-458. doi: 10.1017/cjn.2019.42. Epub 2019 May 22. Can J Neurol Sci. 2019. PMID: 31113500

9

Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.

Benstead TJ, Chalk CH, Parks NE. Benstead TJ, et al. Among authors: parks ne. Cochrane Database Syst Rev. 2014 Dec 20;(12):CD010404. doi: 10.1002/14651858.CD010404.pub2. Cochrane Database Syst Rev. 2014. PMID: 25525951 Review.

10

Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis.

Parks NE, Andreou P, Marrie RA, Fisk JD, Bhan V, Kirkland SA. Parks NE, et al. Mult Scler Relat Disord. 2021 Nov;56:103249. doi: 10.1016/j.msard.2021.103249. Epub 2021 Sep 4. Mult Scler Relat Disord. 2021. PMID: 34517192

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results